Tcellaron Therapeutics

The requested name "Tcellaron Therapeutics" does not appear to match an identifiable company exactly; the closest clear biotech match is Celleron Therapeutics, a University of Oxford spinout oncology company. Celleron developed precision cancer medicines centered on epigenetic modulation and immune reprogramming, with its lead asset zabadinostat (formerly CXD101) studied in lymphoma and microsatellite-stable colorectal cancer, and an ongoing liver cancer program described after the 2023 merger. The company also licensed emactuzumab from Roche for tenosynovial giant cell tumour and incubated SynOx Therapeutics to develop that asset. In January 2023, Celleron merged with Argonaut Therapeutics to form IngenOx Therapeutics, so Celleron no longer appears to operate as an independent active company. Because the queried name is likely a misspelling, this record is provided as the best-match entity rather than an exact match.